Where the evidence stands

This is where the evidence has moved fastest. A 2025 meta-analysis pooling eight studies (6,754 patients) found that good sleep quality was associated with roughly 50% higher clinical pregnancy rates in IVF, and separate cohort work links short sleep to fewer eggs retrieved and, in men, to markedly reduced monthly conception chances and lower testosterone. The stress side is subtler: it is chronic stress load (measured in hair cortisol over months) that predicts IVF outcomes — not how anxious you feel on procedure day. That is why the protocol builds sustained daily regulation habits rather than one-off relaxation. These are associations, not proof of cause, and no trial has yet tested a sleep intervention against IVF outcomes. Guideline position: no major fertility guideline mentions sleep at all — the widest gap between evidence and guidance in preconception care.

Mediterranean-pattern eating shows the strongest and most consistent dietary association with fertility outcomes: pooled analyses report roughly doubled odds of pregnancy or live birth in IVF among high adherers, and a Greek study found a 2.7-fold higher live birth rate in women under 35 in the top adherence group. The one randomised trial to date (PREPARE) showed a six-week dietary change measurably alters the fluid surrounding the developing egg — proof the follicular environment responds quickly, though the trial was too small to test birth rates. The protocol’s protein-first emphasis targets insulin resistance, which recent data show impairs outcomes even in lean women without PCOS. In men, a Mediterranean-style diet nearly halved sperm DNA fragmentation in one trial. Guideline position: every major body agrees diet matters; none prescribes a specific pattern. The structured, couples-based approach here is ahead of consensus.

“Unexplained” infertility often means incompletely investigated. When researchers re-examined couples with this label using laparoscopy, identifiable pathology was found in around 58% of cases — most commonly endometriosis, tubal disease, and adhesions. That is the rationale for looking harder: 3D ultrasound, tubal foam sonography (HyFoSy), a full thyroid panel, fasting insulin, ferritin, and vitamin D. Honesty matters here more than anywhere: well-run trials (TABLET, T4LIFE) show that treating borderline thyroid findings does not improve live birth in most women, so the protocol’s tighter metabolic and thyroid targets are explicitly framed as research questions — things worth measuring and testing, not established treatments. Guideline position: some elements (3D ultrasound, HyFoSy, lifestyle screening) align with current guidelines; the extended metabolic panel goes beyond them and is presented as hypothesis-level.

Supplements are tiered because the evidence is. Tier one is correcting real deficiencies: low ferritin is linked to roughly halved IVF live birth rates in observational data, and vitamin D sufficiency to about a third higher odds of live birth. Above that sits CoQ10, the best-evidenced fertility supplement: a meta-analysis of nine randomised trials found significantly improved pregnancy rates, with the clearest benefit in diminished ovarian reserve and PCOS, and separate trials show improved sperm concentration and motility in men. Melatonin has supportive randomised data at low doses. Frontier agents (NMN, DHEA and similar) remain preclinical or conflicting and are labelled as such. Crucially, no trial has ever tested a multi-supplement protocol as a whole — including this one. Guideline position: deficiency correction is supported; CoQ10 for diminished reserve has moderate evidence; frontier tiers and the integrated stack remain untested.

Sperm concentration has fallen by more than 50% over five decades in a meta-regression of 288 studies, and endocrine-disrupting chemicals are among the implicated causes: higher urinary BPA has been linked to lower egg counts in IVF, and phthalate exposure to reduced semen quality. For men, heat exposure measurably impairs semen parameters, and stopping smoking measurably improves them. Because you cannot test or eliminate everything, the protocol takes a high-yield approach — glass instead of heated plastic, looser underwear, no laptop on lap, smoking cessation — changes that cost almost nothing and carry essentially no downside even where the effect size is uncertain. Guideline position: ASRM and ESHRE acknowledge environmental exposures as relevant but offer little actionable guidance; the protocol turns that acknowledgement into a practical, prioritised list.

The single largest preventable loss in fertility treatment is not biological — it is dropping out. Around 36% of couples discontinue treatment early, most often citing emotional burden, and those who complete their planned cycles achieve roughly 15 percentage points higher cumulative success. This is also why the protocol runs alongside treatment, never instead of it: trials that delayed IVF for lifestyle preparation produced worse outcomes, because age matters more. The “Minimum Viable Safari” — a stripped-down set of non-negotiable habits — is designed to survive the hardest weeks of a cycle, and structured supplement-timing around procedures closes a real safety gap: most patients take supplements, but only a third tell their clinical team. The closest comparable programme trialled to date (PreLiFe) showed no significant benefit, though it was underpowered — which is exactly why we propose formal evaluation. Guideline position: no fertility society recommends a structured preconception programme; treatment–lifestyle coordination is consistent with good clinical practice.